With 3 Granted Patents and 41 Pending, Small Pharma Is On Track To Be One Of Europe’s Biggest Psychedelic Companies

These are exciting times for us all at Small Pharma, with an expanding patent portfolio, a growing team, and continued progress in our clinical trials of SPL026 for the treatment of major depression. 

Small Pharma is both the world’s first regulated clinical trial for DMT-assisted therapy in major depressive disorder as well as the only company that has entered Phase IIa of their trials.


Amanda Siebert in The Dales Report gave us a great write-up summarising our expanding portfolio and how this sets us up to become one Europe’s leading companies researching the potential benefits of psychedelic-assisted therapy for mental health conditions.



To support (our) multiple initiatives, we have expanded our team and will continue to grow as necessary…” Peter Rands, CEO – Small Pharma


About Small Pharma

We’re a mental health drug development company that’s accelerating the development of fast acting antidepressant treatments using DMT based therapies. We’re dedicated to making a difference.

With a focus on innovative approaches and committed to challenging the status quo, we’re targeting the root causes of depression and hoping to unlock the minds of millions.

Get Small Pharma updates

    Investor Deck

    Follow us: